linjc16/ctgov huggingface dataset:
Shuttle Walk Test Performed on a Treadmill Versus a Corridor in Patients With COPD

Study Overview
=================
Brief Summary
-----------------
It is still not clearly known whether doing the walk test in a course is different from doing it on a treadmill in the lack of a ten-meter-long corridor. In case of a positive outcome in this study, we will have an alternative for this test in places where there is not enough room, benefiting the assessment of COPD patients' functional capacity. In the literature, there are still some controversies about performing the test on a treadmill or in a corridor and whether there is interference with the distance walked. Our hypothesis is that there is no interference with the distance walked, and thus we have one more option to perform the test in case there is no 10-meter corridor available.

Detailed Description
-----------------
Spirometry tests will be performed using ULTIMA CPX equipment. Volunteers will perform the tests twice, on different days (see protocol description), in a corridor and on a treadmill, until reaching their limit of tolerance. In the test performed on the treadmill and in the one performed in the corridor, subjects will simultaneously use the VO 2000. And the volunteers will fill out the Saint George's Respiratory Questionnaire (SGRQ).

Official Title
-----------------
Analysis of Metabolic and Ventilatory Demands During the Shuttle Walk Test Performed on a Treadmill Versus a Corridor in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Intervention / Treatment
-----------------
* Other: Treadmill
* Other: Corridor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinically stable not dependent on oxygen to exercise diagnosis of COPD according to the GOLD Exclusion Criteria: cognitive deficit or musculoskeletal in process of exacerbation have performed pulmonary rehabilitation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treadmill<br>The Shuttle is going to play on treadmill | Other: Treadmill<br>* The volunteers will perform the shuttle walk test on the treadmill<br>|
| Active Comparator: Corridor<br>The Shuttle is going to play on corridor | Other: Corridor<br>* The volunteers will perform the shuttle walk test on the corridor<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The distance reached in shuttle walk test |  | two year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COPD, SWTi, Treadmill
The Effect of Folic Acid Administration in the Progression of Microalbuminuria

Study Overview
=================
Brief Summary
-----------------
The development of diabetic nephropathy has been linked to several genetic polymorphisms, including those related with homocysteine metabolism such as the methylenetetrahydrofolate reductase (MTHFR)and the cystathionine-beta-synthase genes. Such alterations are associated with hyperhomocysteinemia, which is a known independent risk factor for the development of endothelial dysfunction and cardiovascular disease. In the Mexican population there is a high prevalence of the C677T MTHFR mutation. The investigators performed this study to evaluate the prevalence of this polymorphism in type 2 diabetic patients with diabetic nephropathy compared with type 2 diabetic patients without nephropathy, besides evaluating the relationship of hyperhomocysteinemia with endothelial dysfunction and microalbuminuria before and after the administration of folic acid. We proposed that the endothelial dysfunction caused by the hyperhomocysteinemia could be reversed after the administration of folic acid.

Official Title
-----------------
Folic Acid Administration Reduces the Progression of Microalbuminuria

Conditions
-----------------
Diabetic Nephropathies, Hyperhomocysteinemia

Intervention / Treatment
-----------------
* Drug: Folic acid
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetes mellitus patients with 5 to 15 years of diagnosis Microalbuminuria (defined as a urinary albumin/creatinine ratio between 30 and 300 mg/g) A1c less than 9% in the last year Exclusion Criteria: Acute diabetic complications A1c greater than 9% in the last year Acute infectious process Hepatic disease Thyroid disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: 1<br>Administration of an oral placebo pill | Drug: Placebo<br>* Administration of an oral placebo pill<br>|
| Experimental: 2<br>Administration of oral folic acid | Drug: Folic acid<br>* Administration of a daily tablet containing 5 mg of folic acid for 4 months.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in albumin excretion rate |  | Four months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in serum homocysteine, thrombomodulin and von Willebrand factor. |  | Four months. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetic nephropathies, Hyperhomocysteinemia, Folic acid, Endothelial dysfunction
Effect of Chronic Statin and Viagra Therapy in Persons With Endothelial Cell Dysfunction

Study Overview
=================
Brief Summary
-----------------
To determine if 6 weeks of daily treatment with Atorvastatin 40 mg alters the immediate effect of Sildenafil Citrate (Viagra, Pfizer Inc, New York, NY) on endothelial function (activity of the artery) as measured by noninvasive peripheral arterial tonography in men and women. Also, to determine if 6 weeks of daily treatment with Atorvastatin 40 mg affects erectile function in men

Official Title
-----------------
The Effect of Chronic Statin Therapy on Peripheral Arterial Tone Response to Sildenafil Citrate (Viagra), and on Erectile Function in Men With Coronary Artery Endothelial Cell Dysfunction

Conditions
-----------------
Endothelial Dysfunction

Intervention / Treatment
-----------------
* Drug: Atorvastatin
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing coronary angiography No previous statin use Age > 18 years old No PDE5-1 use in the past 6 months Exclusion Criteria: Patients with an Acute Coronary Syndrome Patients with Cardiogenic shock Patients > 30% coronary stenosis Patients with unexplained muscle pain Patients with acute liver disease Patients receiving immunosuppressant therapy, azoles, macrolide antibiotics, niacin, L-arginine Patients with serum creatinine > 2.0 Patients with total cholesterol > 200 mmol/l Patients on current statin therapy or clinically indicated to be on statin therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Patients randomized to take 1 40mg Atorvastain pill per day for 6 week study period | Drug: Atorvastatin<br>* 40 mg atorvastatin pill daily<br>|
| Placebo Comparator: 2<br>Patients randomized to 1 40mg placebo pill per day for 6 week study | Drug: placebo<br>* 40 mg pill per day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine if endothelial function as measured by Peripheral Arterial Tonometry improves over a 6 week period while on Atorvastatin. |  | 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine if treatment with Atovastatin affects erectile function in men |  | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
testing for Endothelial Dysfunction and coronary angiography
Adiponectin and Inflammatory Mediators in Mediastinal Adipose Tissues

Study Overview
=================
Brief Summary
-----------------
Coronary artery disease (CAD), the most common type of heart disease, is caused by hardening of the arteries, or atherosclerosis that is an inflammatory process in which immune mechanisms interact with metabolic risk factors to initiate, propagate, and activate lesions in the arterial trees. Epidemiological studies have found that increased cardiovascular risks are associated with increased levels of inflammatory cytokines (eg, interleukin-6 [IL-6] and tumor necrosis factor-alpha[TNF-alpha]) or their hepatic product, C-reactive protein (CRP). Higher expression of interleukin-Ibeta(IL-1beta),IL-6, monocyte chemotactic protein-1 (MCP-1), and TNF-alpha were observed in epicardial adipose tissues in patients with CAD. These findings suggested that the pericoronary tissues could be a source of inflammatory mediators or act as paracrine that lead to vascular inflammation on CAD pathogenesis. However, adiponectin, a kind of adipocytokine, produced and secreted exclusively by adipose tissue, has been reported to have a variety of anti-inflammatory functions against atherosclerosis, resulting in risk reduction for incidence of CAD events. It remains unclear whether adiponectin and inflammatory mediators in mediastinal adipose tissue contribute to CAD. We therefore aim to analyze the expression of adiponectin and inflammatory mediators in mediastinal adipose tissue between patients with CAD and with valve diseases, and to correlate these parameters with clinical atherosclerotic risks, medications (statins or antiplatelet), and blood sugar.

Official Title
-----------------
Adiponectin and Inflammatory Mediators in Mediastinal Adipose Tissues Between Patients With Coronary Artery Diseases and With Valvular Diseases

Conditions
-----------------
Coronary Artery Disease, Atherosclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient underwent CABG or valve surgery in our hospital will be included Exclusion Criteria: liver disease dhronic renal insufficiency neoplastic diseases taking steroids congestive heart failure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>CABG | |
| 2<br>Valve surgery | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Coronary artery disease (CAD), atherosclerosis, mediastinal adipose tissue, adiponectin, inflammatory mediators
Behavioral Intervention for Children With Attention Deficit Hyperactivity Disorder(ADHD)

Study Overview
=================
Brief Summary
-----------------
ADHD children have executive function (EF) impairments,so we randomize the children to the training or a waitlist to improve EF ,adding contingent reinforcement to ascertain whether EF deficits are amenable to the training in children with ADHD.

Official Title
-----------------
Study on the Psychological Behavior Intervention Technology of Attention Deficit Hyperactivity Disorder

Conditions
-----------------
Attention Deficit Hyperactivity Disorder

Intervention / Treatment
-----------------
* Behavioral: A randomized controlled study of Executive Function training for children with ADHD


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis of child ADHD full-scale intelligence quotient (FSIQ) ≥70 stable on medication for ADHD children at least 3 months Exclusion Criteria: individuals with major neurological disorders a diagnosis of schizophrenia, epilepsy, mental retardation or other brain disorders

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Executive function training<br>Children diagnosis of ADHD are randomized to the experimental condition(Executive Function training) or waiting group experimental:participants will receive 12 sessions of executive function training weekly no intervention :waiting participants will not be treated with executive function therapy and keep waiting for 12 weeks for comparison | Behavioral: A randomized controlled study of Executive Function training for children with ADHD<br>* Children diagnosis of ADHD are randomized to the experimental condition(Executive Function therapy) or waiting group experimental:participants will receive 12 sessions of executive function therapy weekly no intervention :waiting participants will not be treated with executive function therapy and keep waiting for 12 weeks for comparison<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in ADHD-rating scale |  | baseline,after the training (12week) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in behavior rating scale of executive function |  | baseline,after the training (12week) | 
| cambridge Neuropsychological Test Automatic Battery |  | baseline,after the training (12week) | 
| Conners |  | baseline,after the training (12week) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Executive function training, child
New Formula for Selection of Proper Size of Endotracheal Tube (ETT) in Children: Ultrasonographic Examination

Study Overview
=================
Brief Summary
-----------------
Choosing the adequate size of endotracheal tube(ETT) in pediatric patients is important in all anesthesiologists, pediatricians, and critical care specialists. Inadequate ETT size will results in soft tissue injury to trachea by means of the pressure, insufficient ventilation, and aspiration, therefore choosing the adequate ETT size has very important clinical aspect.

Detailed Description
-----------------
Choosing the adequate size of endotracheal tube(ETT) in pediatric patients is important in all anesthesiologists, pediatricians, and critical care specialists. Inadequate ETT size will results in soft tissue injury to trachea by means of the pressure, insufficient ventilation, and aspiration, therefore choosing the adequate ETT size has very important clinical aspect. Subglottis is the narrowest portion of upper airway. Thus, ETT size should be determined according to the subglottic diameter. Several conventional methods are available to determine ETT size. These methods are based on the demographic data of patient, such as age, weight, height, but could not be customized for each patient. Ultrasonography (US) is one of the most accurate method to measure the subglottic diameter. Also, US is quick, easy to perform, and non-invasive measure. The investigators tried to measure the exact subglottic diameter with US and analyze the correlation of the diameter and demographical data. Furthermore, the investigators will try to develop the equation that could determine the adequate ETT size based on demographical data, instead of actually measuring the subglottic diameter using US.

Official Title
-----------------
New Formula for Selection of Proper Size of ETT in Children: Ultrasonographic Examination

Conditions
-----------------
Elective Urological Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children undergoing elective urological surgeries Exclusion Criteria: children with anatomical airway problem or prematurely delivered children

Ages Eligible for Study
-----------------
Maximum Age: 7 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ultrasonography children<br>American Society of Anesthesiologists (ASA) I-II children between the age 0-7, undergoing elective urological surgery, such as inguinal hernia repair, orchiopexy, ureteroneocystostomy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ASA I-II children between the age 0-7, general anesthesia
Effectiveness of High Protein Diets in Promoting Weight Loss in Overweight and Obese Subjects.

Study Overview
=================
Brief Summary
-----------------
Several studies have reported greater weight loss when following high meat-protein diets but limited studies have studied high plant-based protein diets. Thus we aim to investigate the effect of high protein diets in weight management and also to investigate the superior protein source in achieving this effect. In addition, we aim to develop dietary intervention strategies that are realistic and sustainable.

Detailed Description
-----------------
Participants will be randomised to either high-protein diets (30% of energy) from animal or plant sources or standard protein diet (15% of energy) weight loss diet for 3 months.

Official Title
-----------------
A Diet Higher in Animal-Based Protein is More Effective in Promoting Weight Loss in Overweight and Obese Individuals Than Other Protein Based Diets.

Conditions
-----------------
Overweight

Intervention / Treatment
-----------------
* Behavioral: High protein diet study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Overweight or obese Age 18 and above Both males and females Live in Illawarra Area of Australia Exclusion Criteria: Regular medication Smoker Food allergies Presence of disease which may alter metabolic rate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: High protein diet study|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Weight & anthropometric measurements at 0 and 3 months |  |  | 
| Energy expenditure |  |  | 
| Substrate oxidation |  |  | 
| Compliance to diets |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood lipids |  |  | 
| Appetite |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Calorimetry, Overweight, Weight loss, Appetite
Atorvastatin in Patients With Ulcerative Colitis

Study Overview
=================
Brief Summary
-----------------
Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease characterized by diffused inflammation of the colon and rectum mucosa; however, the exact underlying mechanisms of UC remain poorly understood. Statins exert numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement, and immunomodulation independent of their basic lipid-lowering property.

Official Title
-----------------
Combination of Atorvastatin and Mesalazine to Enhance Anti-inflammatory Effects and Attenuates Progression of Ulcerative Colitis

Conditions
-----------------
Inflammatory Bowel Diseases

Intervention / Treatment
-----------------
* Drug: Atorvastatin 80mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years Both male and female will be included Negative pregnancy test and effective contraception Exclusion Criteria: Breastfeeding Significant liver and kidney function abnormalities Colorectal cancer patients Patients with severe UC Patients taking rectal or systemic steroids Patients taking immunosuppressives or biological therapies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control Group<br>This group will take 1 g mesalamine three times daily | |
| Active Comparator: Atorvastatin group<br>This group will take 1 g mesalamine three times daily and atorvastatin 80 mg once daily | Drug: Atorvastatin 80mg<br>* Atorvastatin is one of the most effective drugs used to reduce intracellular cholesterol synthesis. it exerts numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement, and immunomodulation independent of its basic lipid-lowering properties<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement in health related quality of life | HRQL questionnaire will be assessed according to a short-form (SF-36) questionnaire. The SF-36 is an indicator of overall health status and contains 10 items. The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100. | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes in the level of inflammatory biomarkers | changes in the level of inflammatory biomarkers such as IL-6, fecal myeloperoxidase | 6 months |